Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2024-11-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于变更注册资本、公司类型、修订《公司章程》并办理工商变更登记的的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 益丰大药房连锁股份有限公司 regarding changes in registered capital, company type, and amendments to the company's articles of association. It details the approval of convertible bond issuance, bond conversion to shares, repurchase and cancellation of restricted stock, and the resulting changes in registered capital and share capital. It also mentions the change in company type and specific amendments to the articles of association. The document is a formal announcement of corporate changes and regulatory filings related to capital and company structure, not a full financial report or detailed management discussion. It is not an annual or interim report, nor a call transcript or earnings release. The content fits best under Capital/Financing Update (CAP) because it involves changes in registered capital, bond issuance, and share capital adjustments. The document length is under 5,000 characters but contains substantive information about capital changes, not merely a report publication announcement. Therefore, the classification is CAP with high confidence.
2024-11-22 Chinese
益丰药房第五届监事会第八次会议决议
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the eighth meeting of the fifth Supervisory Board of Yifeng Pharmacy Chain Co., Ltd. It details decisions such as the termination of a stock transfer agreement and the provision of guarantees for bank credit applications by subsidiaries. The document includes voting results and is dated November 23, 2024. It does not contain financial statements, audit opinions, or detailed financial data. It is not a report itself but an announcement of board-level decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management.
2024-11-22 Chinese
益丰药房关于召开2024年第四次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about the convening of the 2024 fourth extraordinary general meeting of shareholders for Yifeng Pharmacy Chain Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders to participate and vote. There is no financial data, earnings information, or detailed report content. The document is an announcement informing shareholders about the meeting and how to vote, not the actual meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-11-22 Chinese
益丰药房关于使用闲置募集资金委托理财到期赎回并继续委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the redemption of idle raised funds and the continuation of entrusted financial management. It details the amounts, products, and risks involved in the financial products purchased with idle raised funds. The document includes specifics about the board meeting approval and risk disclosures but does not contain financial statements or comprehensive financial performance data. It is a regulatory announcement about the use of raised funds and financial management activities rather than a full financial report or earnings release. The document length is under 5,000 characters and is primarily an announcement of a financial activity related to capital management. Therefore, it fits best under Capital/Financing Update (CAP).
2024-11-14 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2022年限制性股票激励计划部分限制性股票回购注销实施的法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the repurchase and cancellation of restricted shares under a 2022 restricted stock incentive plan by the company. It details the procedures, approvals, and legal compliance related to the stock repurchase and cancellation. The document is not a financial report, earnings release, or management discussion, but a legal opinion on a specific corporate action related to share repurchase and cancellation. This fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares, including repurchase and cancellation of restricted stock.
2024-11-05 Chinese
益丰药房关于使用闲置募集资金委托理财到期赎回并继续委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the redemption and continued investment of idle raised funds into financial products. It details the amounts, types of financial products, approval procedures, risk analysis, and impact on the company. It does not contain comprehensive financial statements or detailed financial performance data. The document is relatively short (2658 characters) and focuses on a specific financing activity related to the use of raised funds. This fits the description of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2024-11-05 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.